USNA

USNA

USD

USANA Health Sciences Inc. Common Stock

$27.180+0.180 (0.667%)

Reaalajas hind

Consumer Defensive
Pakendatud toidud
Ameerika Ühendriigid

Hinnagraafik

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$27.000

Kõrge

$27.190

Madal

$26.460

Maht

0.05M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

512.6M

Tööstusharu

Pakendatud toidud

Riik

United States

Kauplemisstatistika

Keskmine maht

0.22M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $23.1Praegune $27.180Kõrge $49.78

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 23. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

USNA: USANA Health Sciences Inc. Common Stock - Analyzing Recent Moves & What Might Come Next

Stock Symbol: USNA Generate Date: 2025-04-23 13:48:15

Alright, let's break down what's been going on with USANA Health Sciences stock lately. We'll look at the latest news, check out how the price has been moving, and see what some automated predictions are saying.

Recent News Buzz

The big news hitting the wires just yesterday (April 22nd) was USANA's report on their first quarter results for 2025. The headline mentioned net sales hitting $250 million and, importantly, that the company is sticking with its full-year outlook. Now, the news snippet we have doesn't give us all the details like profit or earnings per share, but reiterating the full-year outlook often suggests management feels reasonably confident about where things are headed, even if the sales figure itself needs more context.

Before that, back on April 14th, there was a positive piece about a clinical study showing one of their skincare products, Celavive's Resurfacing Serum, improved skin appearance pretty quickly. That's good news for that specific product line, showing it's backed by some science, which can help sales.

So, the vibe from the news is primarily focused on the recent earnings report. Sticking to the full-year outlook after Q1 is generally seen as a steady sign, not necessarily spectacular, but not a red flag either, based just on the headline. The skincare study is a nice little bonus.

Price Check

Looking at the stock's journey over the last month or so, it's been a bit of a bumpy ride, mostly trending downwards. Back in late March, shares were trading in the $27-$28 range. Then, through early April, the price slid quite a bit, dipping down towards the $24-$25 area.

But then came today, April 23rd. Wow, what a jump! The stock opened significantly higher than yesterday's close and has climbed sharply, hitting highs around $28.19. This kind of move right after an earnings announcement usually means the market liked something in that report, even if the news snippet didn't spell it all out. The volume today isn't huge yet compared to the average, but the price reaction is undeniable.

Now, the AI prediction for today said 0.00% change, which clearly didn't capture this post-earnings surge at all. For tomorrow, the AI actually predicts a dip of about 2.86%, followed by a small gain the day after (+0.96%). This suggests the AI thinks today's big move might not hold entirely.

Outlook & Ideas

Putting it all together, the dramatic price jump today, right after the earnings report, seems to be the dominant factor right now. Despite the stock's recent slide leading up to the report and the AI predicting a dip after today, the market's immediate reaction is strongly positive. This suggests the Q1 results or the reiterated outlook were better received than the prior price trend might have indicated.

So, the apparent near-term leaning, based purely on today's price action tied to the earnings news, seems bullish. The stock is showing strong momentum right now.

What might someone consider doing? Well, the big move has already happened today. Trying to jump in right at the peak of a sudden surge can be risky. One possible strategy could be to watch if this momentum continues or if the stock consolidates (trades sideways) after this initial reaction. If it pulls back slightly but holds above a key level like today's open ($25.50) or even yesterday's close ($24.24), that might be seen by some as a potential entry point if they believe the positive reaction will last.

For managing risk, setting a stop-loss is always smart. A potential level to consider for a stop-loss could be below today's open ($25.50) or perhaps below yesterday's close ($24.24). If the price falls back below those levels, it could signal that today's jump was just a temporary reaction. As for taking profits, the AI predicts a dip tomorrow, which could suggest a very short-term trader might look to lock in gains quickly, but predicting the exact top is impossible. Watching for signs of the momentum slowing down or hitting resistance levels would be key.

Company Context

Just remember, USANA is in the Packaged Foods/Consumer Defensive sector. This means their business is generally less sensitive to economic ups and downs compared to, say, tech or retail. However, they operate with a direct selling model, which has its own unique dynamics and challenges. They are also a relatively small company with a market cap around $531 million, which can sometimes mean more volatile price swings compared to larger companies. The company details also point out some fundamental challenges like negative revenue growth and high debt, which are worth keeping in mind beyond the short-term price action driven by earnings.


Disclaimer: This analysis is for informational purposes only and is based solely on the provided data. It is not financial advice. Stock investing involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

BusinessWire

USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million

Vaata rohkem
USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook
PR Newswire

Clinical Study Shows USANA Celavive's Resurfacing Serum to Improve Appearance of Skin in Just Two Weeks

USANA Health Sciences, Inc., a global leader in cellular nutrition, recently conducted a clinical study on its Celavive Resurfacing Serum to evaluate ...

Vaata rohkem
Clinical Study Shows USANA Celavive's Resurfacing Serum to Improve Appearance of Skin in Just Two Weeks
BusinessWire

USANA Schedules First Quarter 2025 Earnings Release and Conference Call

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings

Vaata rohkem
USANA Schedules First Quarter 2025 Earnings Release and Conference Call

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Langev

Uuendatud kell: 28. apr 2025, 02:18

LangevNeutraalneTõusev

59.6% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Väärtus
Kauplemisjuhend

Sisenemispunkt

$26.86

Võta kasum

$27.72

Peata kahjum

$25.66

Põhitegurid

PDI 14.9 on MDI 10.2 kohal ADX-iga 15.5, mis viitab tõusutrendile
Praegune hind on tugitasemele ($26.96) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 10.4x keskmisest (2,557), mis viitab äärmiselt tugevale ostusurvele
MACD 0.0305 on signaalijoone 0.0332 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.